This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
At 24 weeks, semaglutide reduced the hepatic steatosis index (HSI) by 2.36 and the fibrosis-4 index (FIB-4) by 0.075.
Why it matters
Improving liver health in diabetic patients can reduce the risk of severe liver disease. This study highlights semaglutide's potential benefits beyond blood sugar control.
How the study worked
The study was a multicenter, prospective, pre-post, uncontrolled cohort analysis involving patients with type 2 diabetes treated with semaglutide.
What this study cannot tell us
The study was uncontrolled and lacked a comparison group, which may affect the reliability of the findings.
Read the original research
Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.
Revista clinica espanola, 223(3), 134-143
Citation
Carretero-Gómez, Juana; Carrasco-Sánchez, Francisco Javier; Fernández-Rodríguez, José María; Casado-Escribano, Pedro; Miramontes-González, José Pablo; Seguí-Ripoll, José Miguel; Ena, Javier; Arévalo-Lorido, José Carlos. (2023). Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.. Revista clinica espanola, 223(3), 134-143. https://doi.org/10.1016/j.rceng.2022.12.001